TFE3-rearranged renal cell carcinoma (RCC) has been categorized as a molecularly defined renal carcinoma in the 2022 WHO classification of tumors as it does not demonstrate a specific genotype–phenotype correlation. However, in order to arrive at the diagnosis, recognition of the broad spectrum of cytologic and histologic features that can be seen in TFE3-rearranged RCC is important for differential diagnostic consideration. Reported here is the diagnostic workup of a TFE3-rearranged RCC using very limited tissue sample. The initial evaluation was dependent on the cytomorphologic findings observed on a touch preparation made from the renal mass biopsy, directing appropriate selection of ancillary tests, and leading to a definitive diagnosis.

中文翻译：

---

微创细胞学评估导致 TFE3 重排肾细胞癌的诊断：病例报告

TFE3 重排肾细胞癌 (RCC) 在 2022 年 WHO 肿瘤分类中被归类为分子定义的肾癌，因为它没有表现出特定的基因型 - 表型相关性。然而，为了做出诊断，识别 TFE3 重排 RCC 中广泛的细胞学和组织学特征对于鉴别诊断考虑很重要。这里报告的是使用非常有限的组织样本对 TFE3 重排 RCC 进行的诊断检查。The initial evaluation was dependent on the cytomorphologic findings observed on a touch preparation made from the renal mass biopsy, directing appropriate selection of ancillary tests, and leading to a definitive diagnosis.